| Literature DB >> 33805007 |
Liana Dehelean1,2,3,4, Ana Maria Romosan1, Bianca Oana Bucatos1, Ion Papava1,2, Rita Balint1, Ana Maria Cristina Bortun1, Mirela Marioara Toma5, Simona Bungau5, Radu Stefan Romosan1,2.
Abstract
This study assesses the empathy level, cognitive performance and emotion recognition skills of remitted patients with schizophrenia, schizoaffective disorder and bipolar disorder, and also explores the relationship between impairments in the mentioned domains. The study was performed on 77 subjects divided into two groups: PAT sample (N = 37) included remitted patients with either schizophrenia, schizoaffective or bipolar disorder who were compared with healthy control subjects from the HC sample (N = 40). Along with sociodemographic and clinical data, empathy levels (using EQ (Empathy Quotient) scale), the ability to recognize another person's emotional state (using RMET (Reading the Mind in the Eyes Test)), and cognitive performance (using MoCA (Montreal Cognitive Assessment) Scale) were investigated. The intensity of the psychiatric symptoms was measured with BPRS-E (Brief Psychiatric Rating Scale-Expanded). The remitted patients had lower EQ (p = 0.02) and RMET (p < 0.0001) scores than the healthy subjects. In the PAT group, RMET scores were positively correlated with MoCA total scores. Both EQ and RMET scores were negatively correlated with BPRS-E total scores. Psychiatric disorder was a significant predictor for deficits in emotion recognition. There were no significant differences in RMET, EQ and MoCA scores between patients with respect to diagnosis, the type of antipsychotic or the associated medication. In both samples, females had higher empathy levels (p = 0.04) and better emotion recognition abilities (p = 0.04) than males. Patients with schizophrenia, schizoaffective or bipolar disorder, currently in remission, displayed lower empathy levels and poorer emotion recognition skills than healthy subjects. Poor emotion recognition skills were associated with symptom severity and impairments in global cognition.Entities:
Keywords: bipolar disorder; cognitive function; neurocognitive deficits; remitted patients; schizoaffective; schizophrenia; social cognition
Year: 2021 PMID: 33805007 PMCID: PMC8063917 DOI: 10.3390/healthcare9040365
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Sample demographic characteristics.
| Demographic Characteristics | PAT | HC | 1 PAT vs. HC | ||||
|---|---|---|---|---|---|---|---|
| N = 37 | % | N = 40 | % | ||||
| Gender | Males | 16 | 43.2 | 11 | 27.5 | χ2: 2.09 | 0.15 |
| Females | 21 | 56.8 | 29 | 72.5 | |||
| Age (years) | M, SD | 41.65 | 9.23 | 39.02 | 15.7 | U = 554; Z = −1.89 | 0.06 |
| Years of education | 1–8 | 4 | 10.8 | 0 | 0 | χ2: 7.03 | 0.03 |
| 9–12 | 24 | 37.8 | 10 | 25 | |||
| >12 | 19 | 51.4 | 30 | 75 | |||
| Professional status | Employed | 18 | 48.6 | 40 | 100 | χ2: 27.26 | <0.0001 |
| Unemployed | 19 | 51.4 | 0 | 0 | |||
Legend: PAT, patients; HC, healthy controls; M, mean; SD, standard deviation; 1 Chi square test (χ2) or Mann–Whitney U test.
Sample clinical characteristics.
| Sample Clinical Characteristics | PAT | HC | 1 PAT vs. HC | ||||
|---|---|---|---|---|---|---|---|
| N = 37 | % | N = 40 | % | ||||
| Diagnosis | Schizophrenia | 26 | 70.3 | - | - | - | - |
| Schizoaffective disorder | 6 | 16.2 | |||||
| Bipolar disorder | 5 | 13.5 | |||||
| Antipsychotic treatment | Aripiprazole | 6 | 16.2 | - | - | - | - |
| Clozapine | 5 | 13.5 | |||||
| Olanzapine | 14 | 37.9 | |||||
| Paliperidone | 5 | 13.5 | |||||
| Quetiapine | 3 | 8.1 | |||||
| Risperidone | 4 | 10.8 | |||||
| Mood stabilizer or antidepressant | Yes | 20 | 54.1 | - | - | - | - |
| No | 17 | 45.9 | |||||
| Alcohol misuse | Yes | 5 | 13.5 | 0 | 0 | χ2: 5.78 | 0.02 |
| No | 32 | 86.5 | 40 | 100 | |||
| Smoking | Yes | 10 | 27.1 | 9 | 22.5 | χ2: 0.21 | 0.65 |
| No | 27 | 72.9 | 31 | 77.5 | |||
| RMET correct answers, SD | 19.27 | 5.22 | 25.3 | 4.31 | U:274, Z = −4.76 | <0.0001 | |
| EQ total score, SD | 37.43 | 10.34 | 43.07 | 10.81 | U:508, Z = −2.36 | 0.02 | |
| BPRS-E total score, SD | 35.54 | 9.83 | 24.55 | 1.03 | U:91, Z = −7.36 | <0.0001 | |
Legend: PAT, patients; HC, healthy controls; M, mean; SD, standard deviation; RMET, Reading the Mind in the Eyes Test; EQ, Empathy Quotient; BPRS-E, Brief Psychiatry Rating Scale—Expanded, 1 Chi square test (χ2) or Mann–Whitney U test.
MoCA scores of the PAT sample.
| MoCA | PAT: Mean Scores (SD) | HC: Mean Scores (SD) | Mann–Whitney U Test | |
|---|---|---|---|---|
| Total | 25.16 (3.61) | 29.69 (0.51) | 111; −7.22 | <0.0001 |
| Executive functions (EF) | 2.54 (1.28) | 3.03 (0.25) | 317; −5.94 | <0.0001 |
| Visuospatial abilities (VSA) | 3.41 (0.83) | 3.95 (0.21) | 553; −4.15 | <0.0001 |
| Language (LG) | 4.43 (0.6) | 5 (0) | 430; −5.45 | <0.0001 |
| Memory (MEM) | 3.45 (1.26) | 4.95 (0.21) | 237; −6.64 | <0.0001 |
| Attention (AT) | 5.21 (1.08) | 5.88 (0.32) | 520; −4.12 | <0.0001 |
| Orientation (OT) | 5.89 (0.65) | 5.97 (0.15) | 902; −0.03 | 0.97 |
Legend: PAT, patients; HC, healthy controls; MoCA, Montreal Cognitive Assessment; SD, standard deviation.
Correlation coefficients and their statistical significance for RMET, EQ, BPRS and MoCA scores for the PAT sample.
| Correl. Coef. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 1 | - | - | - | - | - | - | - | - | - |
|
| 0.94 (0.058) | 1 | - | - | - | - | - | - | - | - |
|
| −0.46 (0.005 **) | −0.38 (0.02 *) | 1 | - | - | - | - | - | - | - |
|
| 0.35 (0.03 *) | −0.02 (0.91) | −0.37 (0.02 *) | 1 | - | - | - | - | - | - |
|
| 0.24 (0.15) | −0.16 (0.33) | −0.09 (0.60) | 0.78 (<0.0001 **) | 1 | - | - | - | - | - |
|
| 0.20 (0.22) | 0.10 (0.54) | −0.18 (0.29) | 0.67 (<0.0001 **) | 0.58 (<0.0001 ***) | 1 | - | - | - | - |
|
| 0.17 (0.31) | −0.12 (0.46) | −0.10 (0.55) | 0.39 (0.02 *) | 0.11 (0.46) | 0.29 (0.07) | 1 | - | - | - |
|
| 0.18 (0.28) | 0.21 (0.21) | −0.36 (0.03 *) | 0.78 (<0.0001 **) | 0.52 (0.001 **) | 0.42 (0.01 *) | 0.15 (0.37) | 1 | - | - |
|
| 0.40 (0.01 *) | 0.16 (0.33) | −0.49 (0.002 **) | 0.32 (0.04 *) | 0.07 (0.68) | −0.02 (0.86) | 0.06 (0.73) | 0.32 (0.05) | 1 | - |
|
| 0.21 (0.19) | −0.16 (0.33) | −0.25 (0.13) | 0.28 (0.09) | 0.20 (0.23) | 0.31 (0.06) | −0.16 (0.32) | 0.29 (0.08) | 0.30 (0.07) | 1 |
Legend: 1—RMET, Reading the Mind in the Eyes Test; 2—EQ, Empathy Quotient; 3—BPRS-E, Brief Psychiatry Rating Scale-Expanded; MoCA, Montreal Cognitive Assessment; 4—MoCA total; 5—MoCA executive; 6—MocA visuo-spatial; 7—MoCA language; 8—MoCA memory; 9—MoCA attention; 10—MoCA orientation. * Correlation is significant at the 0.05 level (2-tailed); ** Correlation is significant at the 0.01 level (2-tailed). *** Correlation is significant at the 0.001 level (2-tailed).